WORLD Fourth large-scale COVID-19 vaccine trial starts in US

WORLD

Fourth large-scale COVID-19 vaccine trial starts in US

Xinhua

09:19, September 24, 2020

WASHINGTON, Sept. 23 (Xinhua) - A fourth Phase 3 clinical trial evaluating an investigational COVID-19 vaccine has begun enrolling adult volunteers, the U.S. National Institutes of Health (NIH) announced on Wednesday.

VCG111294157927.jpg

(File photo: CFP)

The trial is designed to evaluate if the investigational Janssen COVID-19 vaccine JNJ-78436725 can prevent symptomatic COVID-19 after a single dose regimen, the NIH said in a release.

Up to 60,000 volunteers will be enrolled in the trial at up to nearly 215 clinical research sites in the United States and internationally.

The Janssen Pharmaceutical Companies of Johnson & Johnson developed the investigational vaccine, and is leading the clinical trial as regulatory sponsor.

The Janssen vaccine candidate is a recombinant vector vaccine that uses a human adenovirus to express the SARS-CoV-2 spike protein in cells.

The trial is designed primarily to determine if the investigational vaccine can prevent moderate to severe COVID-19 after a single dose. It also aims to understand if the vaccine can prevent COVID-19 requiring medical intervention and if the vaccine can prevent milder cases of COVID-19 and asymptomatic SARS-CoV-2 infection, according to the NIH. 

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue